(Q37738558)

22 August 2017

1 reference

title

Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification (English)

1 reference

22 August 2017

1 reference

2

Luis E Fayad

0 references

Jason R Westin

series ordinal

1

object named as

Jason R Westin

1 reference

22 August 2017

publication date

1 October 2009

1 reference

Current hematologic malignancy reports

22 August 2017

published in

1 reference

22 August 2017

volume

4

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

218-224

1 reference

Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-009-0029-Y

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

12 December 2020

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

1 reference

12 December 2020

Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase

1 reference

12 December 2020

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

12 December 2020

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

12 December 2020

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma

1 reference

12 December 2020

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

1 reference

12 December 2020

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

12 December 2020

Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

1 reference

12 December 2020

A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'

1 reference

12 December 2020

BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?

1 reference

12 December 2020

CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor

1 reference

12 December 2020

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

1 reference

12 December 2020

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

12 December 2020

Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course

1 reference

12 December 2020

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma

1 reference

12 December 2020

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

1 reference

12 December 2020

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

1 reference

12 December 2020

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Mol

1 reference

12 December 2020

Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies

1 reference

12 December 2020

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

1 reference

12 December 2020

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

1 reference

12 December 2020

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

1 reference

12 December 2020

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

1 reference

12 December 2020

Stromal gene signatures in large-B-cell lymphomas

1 reference

12 December 2020

Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases

1 reference

12 December 2020

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

1 reference

12 December 2020

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

12 December 2020

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas

1 reference

12 December 2020

Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance

1 reference

12 December 2020

Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma

1 reference

12 December 2020

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

12 December 2020

Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas

1 reference

12 December 2020

Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family

1 reference

12 December 2020

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab

1 reference

12 December 2020

Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma

1 reference

12 December 2020

Prognostic biomarkers in diffuse large B-cell lymphoma

1 reference

12 December 2020

A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index

1 reference

12 December 2020

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

12 December 2020

Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

1 reference

12 December 2020

Molecular diagnosis of Burkitt's lymphoma

1 reference

12 December 2020

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

12 December 2020

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

1 reference

12 December 2020

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

12 December 2020

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

12 December 2020

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

1 reference

12 December 2020

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

1 reference

12 December 2020

10.1007/S11899-009-0029-Y

Identifiers

DOI

1 reference

22 August 2017

1 reference